Tokio Marine Asset Management Co. Ltd. lifted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 26.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 18,457 shares of the company's stock after acquiring an additional 3,829 shares during the period. Tokio Marine Asset Management Co. Ltd.'s holdings in IDEXX Laboratories were worth $7,751,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd purchased a new position in IDEXX Laboratories during the 1st quarter valued at about $172,000. S Bank Fund Management Ltd acquired a new position in shares of IDEXX Laboratories in the first quarter worth $535,000. National Pension Service increased its stake in shares of IDEXX Laboratories by 7.4% in the first quarter. National Pension Service now owns 126,400 shares of the company's stock worth $53,082,000 after acquiring an additional 8,752 shares during the last quarter. LGT Group Foundation acquired a new position in shares of IDEXX Laboratories in the first quarter worth $466,000. Finally, LGT Fund Management Co Ltd. acquired a new position in shares of IDEXX Laboratories in the first quarter worth $248,000. Institutional investors and hedge funds own 87.84% of the company's stock.
Insider Transactions at IDEXX Laboratories
In related news, EVP Nimrata Hunt sold 1,200 shares of IDEXX Laboratories stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $656.53, for a total transaction of $787,836.00. Following the sale, the executive vice president directly owned 16,807 shares of the company's stock, valued at $11,034,299.71. This trade represents a 6.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael Lane sold 8,411 shares of IDEXX Laboratories stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $627.74, for a total value of $5,279,921.14. Following the sale, the executive vice president directly owned 7,132 shares in the company, valued at approximately $4,477,041.68. This trade represents a 54.11% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 54,176 shares of company stock worth $34,060,678. 0.98% of the stock is currently owned by insiders.
Analyst Ratings Changes
IDXX has been the topic of a number of research reports. Piper Sandler reaffirmed a "neutral" rating and issued a $700.00 price target (up from $510.00) on shares of IDEXX Laboratories in a research note on Monday. Leerink Partners upped their price target on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. Morgan Stanley upped their price target on shares of IDEXX Laboratories from $722.00 to $765.00 and gave the stock an "overweight" rating in a research note on Friday. Jefferies Financial Group assumed coverage on shares of IDEXX Laboratories in a research note on Tuesday, July 1st. They issued a "buy" rating and a $625.00 price target on the stock. Finally, Stifel Nicolaus set a $640.00 target price on shares of IDEXX Laboratories in a research report on Monday, August 4th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, IDEXX Laboratories currently has an average rating of "Moderate Buy" and a consensus target price of $649.44.
Read Our Latest Stock Analysis on IDEXX Laboratories
IDEXX Laboratories Stock Performance
NASDAQ:IDXX traded down $3.11 during mid-day trading on Friday, hitting $650.84. 418,031 shares of the company's stock traded hands, compared to its average volume of 851,260. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. The firm has a 50 day moving average of $555.92 and a two-hundred day moving average of $485.51. The firm has a market capitalization of $52.07 billion, a price-to-earnings ratio of 54.19, a price-to-earnings-growth ratio of 4.23 and a beta of 1.49. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $688.12.
IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, beating the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%. The company had revenue of $1.11 billion during the quarter, compared to analysts' expectations of $1.06 billion. During the same period in the prior year, the business earned $2.44 earnings per share. IDEXX Laboratories's revenue for the quarter was up 10.6% compared to the same quarter last year. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.
About IDEXX Laboratories
(
Free Report)
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Recommended Stories

Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.